Skip to main
NMRA

NMRA Stock Forecast & Price Target

NMRA Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Neumora Therapeutics is poised for success with their expanded pipeline addressing underserved neuropsychiatric disorders and neurodegenerative diseases. With promising data from multiple clinical trials and a strong financial position, the company has the potential for significant growth in the future. The company's management team has demonstrated their ability to successfully advance their products through the development process, giving investors confidence in the company's capabilities. This, combined with the potential for multiple upcoming valuation swing events, leads to a positive outlook for Neumora Therapeutics and its potential for long-term success.

Bears say

Neumora Therapeutics is a clinical-stage biopharmaceutical company with a pipeline of seven clinical and preclinical programs targeting neuropsychiatric disorders and neurodegenerative diseases. However, despite the positive outlook on their lead program NMRA-898 for schizophrenia, their other pipeline programs are still in early stages and face a lot of competition. Additionally, NMRA's financials may be impacted by the need for further clinical studies and potential safety concerns in the future. Overall, the stock's outlook may be negative due to the uncertainty and risk associated with their pipeline and financials.

NMRA has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neumora Therapeutics Inc (NMRA) Forecast

Analysts have given NMRA a Buy based on their latest research and market trends.

According to 6 analysts, NMRA has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neumora Therapeutics Inc (NMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.